Cantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Guidance

Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss May 8, 2015 8:46 AM Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15cMay 7, 2015 4:16 PM Jazz Pharmaceuticals Announces First Quarter 2015 Financial ResultsMay 7, 2015 4:06 PM Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program UpdateMay 7, 2015 4:05 PM